Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most key points align with the label excerpt (indication limited to uncomplicated acute cystitis; not indicated for pyelonephritis; single-dose regimen; metoclopramide interaction; CDAD warning). However, several claims introduce additional clinical consequence/interpretation and treatment-selection guidance not explicitly stated in the provided label text, and one claim defines pyelonephritis anatomy that is not supported by the label excerpts.
Category Scores
Accurate Statements
Fosfomycin tromethamine is an antibiotic indicated for specific urinary tract infections.
INDICATIONS AND USAGE: indicated only for uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of E. coli and Enterococcus faecalis.
Fosfomycin tromethamine is not intended for kidney infections.
INDICATIONS AND USAGE: not indicated for treatment of pyelonephritis or perinephric abscess.
DailyMed labeling for fosfomycin tromethamine states it is not indicated for pyelonephritis.
INDICATIONS AND USAGE: not indicated for treatment of pyelonephritis.
Fosfomycin tromethamine is meant for uncomplicated urinary tract infections within its approved use, not for upper urinary tract infections such as pyelonephritis.
INDICATIONS AND USAGE: indicated only for uncomplicated urinary tract infections (acute cystitis); not indicated for pyelonephritis.
Unsupported Statements
Pyelonephritis is an infection of the kidney tissue.
The provided label excerpt does not define pyelonephritis or describe kidney tissue involvement.
Using fosfomycin tromethamine for suspected pyelonephritis risks undertreating an infection involving the kidney.
The provided label excerpt states it is not indicated for pyelonephritis, but does not explicitly state risks of undertreatment for use in suspected pyelonephritis.
Undertreating a kidney infection can lead to persistent symptoms or progression to more severe illness.
The provided label excerpt does not describe clinical outcomes associated with undertreatment of pyelonephritis.
DailyMed’s “not indicated for pyelonephritis” statement is meant to steer clinicians away from using it as the treatment for kidney infections.
The label excerpt provides indication limits but does not explicitly state intent/messaging to steer clinicians.
DailyMed labeling draws a distinction between lower urinary tract infections (where fosfomycin may be appropriate) and pyelonephritis (where different therapies are required).
The label excerpt distinguishes acute cystitis (uncomplicated) from pyelonephritis by indication, but does not explicitly discuss lower vs upper tract terminology or that different therapies are required.
The correct treatment choice for pyelonephritis follows pyelonephritis guidance and should be based on clinical assessment and local practice.
The provided label excerpt does not provide guidance on what to use for pyelonephritis, nor does it instruct clinicians to follow external guidance or local practice for treatment selection.
Contradictions
Low
AI Statement
Fosfomycin tromethamine is not intended for kidney infections.
Label Reference
INDICATIONS AND USAGE: not indicated for pyelonephritis or perinephric abscess (kidney-related indications).
Important Omissions
Any mention of the label’s specific dosing regimen for uncomplicated acute cystitis in women (one sachet; do not exceed one single dose; may be taken with or without food).
Importance:
Moderate
Key label safety information included in the excerpt (e.g., CDAD warning; adverse reaction rates; contraindication for hypersensitivity; metoclopramide interaction).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The label-consistent parts support appropriate indication limitation (not for pyelonephritis). However, several statements extrapolate clinical consequences and treatment-selection guidance not contained in the provided label text, which could lead to overconfident interpretation beyond labeling.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims extend beyond the provided label excerpt (definition of pyelonephritis; specific consequences of undertreatment; clinician-steering intent; external treatment-selection guidance).
Suggested Improvement
Limit wording to label-supported points: indication only for uncomplicated acute cystitis in women and explicitly not indicated for pyelonephritis/perinephric abscess; avoid adding specific outcome/risk narratives or treatment-selection instructions not present in the provided label text.